Guest Profile

Dr. Michael Harrison

Dr. Harrison specializes in treating people with genitourinary cancers, such as bladder, prostate, testicular and kidney cancer. He is a clinical trial investigator in the Phase II IMvigor 210 study, which evaluated the safety and efficacy of TECENTRIQ in bladder cancer.